Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 17

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 approximately $10.3 million, and a working capital deficit of approximately $9.4 million. The Company's unrestricted cash and cash equivalents at March 31, 2025 represented funds received under grant agreements that generally may be applied solely toward direct costs for carrying out the respective projects under those grant agreements. See Note 10, Grant Awards. For the three months ended March 31, 2025, the Company incurred a net loss of approximately $4.4 million and had negative cash flow from operations of approximately $5.5 million. Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. The Company will need to raise substantial additional capital to continue to fund its operations and to successfully execute its current strategy. The Company is in ongoing discussions with potential third-party sources of additional capital, and the Company will continue to evaluate and may pursue a variety of capital raising options, including sales of equity, debt financings, government or other grant funding, collaborations, structured financings, and strategic alliances or other similar types of arrangements. However, the Company's ability to raise additional capital will depend on a variety of factors, many aspects of which are not entirely within its control, and there can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. In addition, the delisting of the Company's common stock from Nasdaq could substantially impair its ability to raise capital.If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its condensed consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The Company's condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.Segment InformationOperating segments are defined as components of an enterprise about which discrete financial information is available for evaluation the Chief Operating